for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Virbac SA

VIRB.PA

Latest Trade

234.50EUR

Change

27.50(+13.29%)

Volume

48,057

Today's Range

221.00

 - 

239.00

52 Week Range

109.00

 - 

239.00

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
207.00
Open
222.00
Volume
48,057
3M AVG Volume
0.20
Today's High
239.00
Today's Low
221.00
52 Week High
239.00
52 Week Low
109.00
Shares Out (MIL)
8.43
Market Cap (MIL)
1,750.81
Forward P/E
33.35
Dividend (Yield %)
--

Latest Developments

More

Virbac Q3 Revenue Up At 233.6 Million Euros

Virbac H1 Operating Profit Up At EUR 50.0 Mln

Euronext Announces Quarterly Revision Of French Indices

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Virbac SA

Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. It also offers food and electronic identification chips for pets.

Industry

Biotechnology & Drugs

Contact Info

13eme rue LID, Bp 27, Carros Cedex

+33.4.92087100

https://corporate.virbac.com

Executive Leadership

Marie-Helene Dick

Chairwoman of the Supervisory Board

Sebastien Huron

Chairman of the Management Board

Christian Karst

Chief Executive Officer, Director of Development, Member of the Management Board

Pierre Madelpuech

Vice Chairman of the Supervisory Board

Habib Ramdani

Chief Financial Officer, Member of the Management Board

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.9K

2017

0.9K

2018

0.9K

2019(E)

0.9K
EPS (EUR)

2016

4.110

2017

3.520

2018

3.630

2019(E)

6.208
Price To Earnings (TTM)
50.90
Price To Sales (TTM)
1.94
Price To Book (MRQ)
3.57
Price To Cash Flow (TTM)
20.10
Total Debt To Equity (MRQ)
107.12
LT Debt To Equity (MRQ)
85.94
Return on Investment (TTM)
3.77
Return on Equity (TTM)
2.77

Latest News

Latest News

Virbac 2018 operating profit grows helped by U.S. market

French veterinary pharmaceutical company Virbac said 2018 operating profit before depreciation of assets arising from acquisitions grew by 9.6 percent, helped by a strong performance in the U.S. and all other countries except Chile.

France's Virbac sees higher margin as U.S profitability improves

French veterinary pharmaceutical company Virbac said on Monday it was raising its full year operating margin forecast as a result of improved profitability in the United States and growth in emerging markets and Europe.

BRIEF-Virbac Q1 Revenue Up At 193.5 Million Euros

* VIRBAC : 2018 FIRST QUARTER REVENUE ROSE BY +3.3% AT COMPARABLE EXCHANGE RATES

Animal medicines group Virbac sees slow sales growth this year

French veterinary pharmaceutical company Virbac expects a low-single-digit increase in revenue at constant exchange rates this year partly due to weakness in the U.S. market, it said on Wednesday.

BRIEF-Virbac FY Net Profit From Ordinary Activities Down 16.3 Pct At 29.5 Million Euros

* VIRBAC: OPERATING PROFIT FROM ORDINARY ACTIVITIES 2017 COMPARABLE TO 2016

BRIEF-Virbac Q4 Sales Up At 231.5 Million Euros

* ANNUAL SALES COMPARABLE TO 2016 AT CONSTANT EXCHANGE RATES AFTER STRONG FOURTH-QUARTER GROWTH

BRIEF-Virbac postpones its option to buy Centrovet for three years

* REG-VIRBAC : AQUACULTURE: VIRBAC POSTPONES ITS OPTION TO BUY CENTROVET FOR THREE YEARS

BRIEF-Virbac Q3 sales fall to 192.7 million euros

* REG-VIRBAC: QUARTERLY SALES AFFECTED BY DISTRIBUTOR DESTOCKING IN THE UNITED STATES

Virbac cuts full-year revenue forecast amid still weak US sales

French veterinary pharmaceutical firm Virbac cut its full-year outlook on Monday, saying it now expected revenue to be little changed from last year after a fall in U.S. sales affected its first-half earnings.

BRIEF-Virbac H1 net profit group share rises to 13.9 ‍million euros

* H1 NET PROFIT GROUP SHARE EUR 13.9 MILLION VERSUS EUR 13.1 MILLION YEAR AGO

BRIEF-Creso Pharma signs commercialisation agreement with Virbac

* Signed a commercialisation agreement with Virbac, for the launch of its hemp‐based complementary animal feed products Source text for Eikon: Further company coverage:

BRIEF-Virbac Q‍2 consolidated revenue up to 234.8 million euros

* CONSOLIDATED REVENUE IN Q2 AMOUNTED TO EUR 234.8 MILLION, UP SHARPLY BY +7.5% COMPARED TO SAME PERIOD IN 2016 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Virbac says Sébastien Huron to become new Chairman

* REG-VIRBAC : SÉBASTIEN HURON WILL BECOME THE NEW CHAIRMAN OF THE EXECUTIVE BOARD AS OF DECEMBER 2017

BRIEF-Virbac signs a research agreement with Bio-Gene

* VIRBAC SA - VIRBAC SIGNS A RESEARCH AGREEMENT WITH BIO-GENE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biocorp signs an industrialization contract with Virbac

* INDUSTRIALIZATION CONTRACT TOTALING €1 MILLION FOR THE MANUFACTURING OF AN INNOVATIVE ADMINISTRATION AND CLOSURE SYSTEM COMPATIBLE WITH VIALS

BRIEF-Virbac Q1 sales fall to 199.7 million euros

* First quarter 2017 sales down, strongly impacted by stock effects in the distribution

BRIEF-Virbac FY operating profit 69.0 million euros, up 100 percent

* FY operating profit 69.0 million euros ($73.59 million), up 100 percent

BRIEF-Virbac Q4 net revenue up to 225.7 million euros

* Q4 net revenue 225.7 million euros ($241.41 million) versus 206.2 million euros year ago

BRIEF-Virbac Q3 revenue rises to 216.3 million euros

* Reported on Thursday 9-month revenue 646.2 million euros ($723.81 million) versus 646.0 million euros year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up